Factors For Boehringer Ingelheim's Serialization And Aggregation Investments

By John Carlin

The introduction of the Falsified Medicines Directive in the EU and the Drug Supply Chain Security Act in the US was a transformational trigger to the whole pharmaceutical industry. It changed how companies package, distribute, and export their products.

For Boehringer Ingelheim, an international biopharmaceutical company, it was essential to find solutions that would not only fulfill compliance requirements but also be integrated into the existing manufacturing process without becoming a production bottleneck. Learn how Boehringer Ingelheim carefully designed and implemented new processes supported by reliable technological solutions to strategically approach serialization and traceability.